

# Bernard Ttu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11865417/bernard-tetu-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

2,364  
citations

21  
h-index

30  
g-index

30  
ext. papers

2,781  
ext. citations

12  
avg, IF

4.3  
L-index

#	Paper	IF	Citations
29	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , <b>2019</b> , 25, 1615-1626	50.5	25
28	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , <b>2019</b> , 35, 414-427.e6	24.3	97
27	Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer. <i>Pathology Research and Practice</i> , <b>2019</b> , 215, 152369	3.4	1
26	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , <b>2019</b> , 176, 831-843.e23	36.2	214
25	The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 789-798	4	4
24	Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. <i>BJU International</i> , <b>2019</b> , 123, 624-631	5.6	10
23	Association between physical activity and the expression of mediators of inflammation in normal breast tissue among premenopausal and postmenopausal women. <i>Cytokine</i> , <b>2018</b> , 102, 151-160	4	6
22	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , <b>2017</b> , 541, 359-364	50.4	320
21	A Prostate Cancer "Nimbus": Genomic Instability and SchLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , <b>2017</b> , 72, 665-674	10.2	98
20	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , <b>2017</b> , 72, 22-31	10.2	28
19	Impacts of a Large Decentralized Telepathology Network in Canada. <i>Telemedicine Journal and E-Health</i> , <b>2016</b> , 22, 246-50	5.9	9
18	Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis. <i>Human Pathology</i> , <b>2015</b> , 46, 739-45	3.7	21
17	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 736-45	36.3	306
16	Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis. <i>Modern Pathology</i> , <b>2014</b> , 27, 1394-404	9.8	22
15	Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. <i>Cancer Prevention Research</i> , <b>2014</b> , 7, 766-76	3.2	24
14	Diagnosis of urothelial carcinoma from urine. <i>Modern Pathology</i> , <b>2009</b> , 22 Suppl 2, S53-9	9.8	124
13	Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. <i>Modern Pathology</i> , <b>2008</b> , 21, 1002-10	9.8	43

12	The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. <i>Breast Cancer Research</i> , <b>2006</b> , 8, R28	8.3	95
11	History of gynecological pathology. XVIII: Dr. Louis Berger. <i>International Journal of Gynecological Pathology</i> , <b>2005</b> , 24, 385-90	3.2	2
10	ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. <i>Modern Pathology</i> , <b>2005</b> , 18, 83-9	9.8	80
9	Markers of neck failure in oral cavity and oropharyngeal carcinomas treated with radiotherapy. <i>Head and Neck</i> , <b>2001</b> , 23, 87-93	4.2	9
8	Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases. <i>Breast Cancer Research and Treatment</i> , <b>1999</b> , 55, 137-47	4.4	15
7	Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. <i>Journal of Urology</i> , <b>1999</b> , 162, 2024-8	2.5	48
6	Ovarian metastases of breast carcinoma. A clinicopathologic study of 59 cases. <i>Cancer</i> , <b>1989</b> , 64, 892-8	6.4	95
5	Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. <i>Cancer</i> , <b>1987</b> , 59, 977-82	6.4	136
4	Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. <i>Cancer</i> , <b>1987</b> , 59, 1803-9	6.4	241
3	Small cell carcinoma of the kidney. A clinicopathologic, immunohistochemical, and ultrastructural study. <i>Cancer</i> , <b>1987</b> , 60, 1809-14	6.4	57
2	Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. <i>Cancer</i> , <b>1986</b> , 58, 278-86	6.4	126
1	Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). II. An immunohistochemical and electron microscopic study. <i>Cancer</i> , <b>1986</b> , 58, 287-98	6.4	68